申请人:Boehringer Mannheim GmbH
公开号:US05414088A1
公开(公告)日:1995-05-09
The invention concerns compounds of formula I ##STR1## where R.sup.1 is hydrogen, C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl or C.sub.3 -C.sub.7 -cycloalkyl, R.sup.2 is C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl, cyano, carboxy [carbonyl substituted by hydroxyl], C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino or hydrazino or R.sup.1 and R.sup.2 together are C.sub.2 -C.sub.6 -alkylidene or C.sub.3 -C.sub.6 -cycloalkylidene or R.sup.1 and R.sup.2, together with the carbon atoms to which they are attached, form a C.sub.3 -C.sub.7 -spirocycle, n is 0 or 1, R.sup.3 is hydrogen, C.sub.1 -C.sub.8 -alkyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -alkynyl, C.sub.3 -C.sub.7 -cycloalkyl, benzyl, carboxy-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkyloxycarbonyl-C.sub.1 -C.sub.6 -alkyl or di-C.sub.1 -C.sub.6 -alkyloxophosphinyl-C.sub.1 -C.sub.6 -alkyl and R.sup.4 -R.sup. 6 are as in the specification. These compounds of formula I serve for the preparation of medicaments to inhibit erythrocyte and thrombocyte aggregation. Therefore, these compounds are useful for the treatment of diseases where these aggregations occur such as arterial occlusive or ischaemic conditions, venous insufficiency or diabetes mellitus.
本发明涉及式I的化合物:##STR1## 其中R1为氢、C1-C6烷基、C2-C6烯基或C3-C7环烷基,R2为C1-C6烷基、C2-C6烯基、氰基、羧基[羟基取代的羰基]、C1-C6烷氧基、氨基、C1-C6烷基氨基、二C1-C6烷基氨基或肼基,或R1和R2一起为C2-C6烷基亚甲基或C3-C6环烷基亚甲基,或者R1和R2连同它们所连接的碳原子形成C3-C7螺环,n为0或1,R3为氢、C1-C8烷基、C2-C6烯基、C2-C6炔基、C3-C7环烷基、苄基、羧基-C1-C6烷基、C1-C6烷氧羰基-C1-C6烷基或二C1-C6烷氧基膦酰基-C1-C6烷基,R4-R6如说明书所述。这些式I的化合物用于制备药物,以抑制红细胞和血小板聚集。因此,这些化合物对于治疗这些聚集发生的疾病非常有用,例如动脉闭塞性或缺血性疾病、静脉不全或糖尿病。